RT Journal Article SR Electronic T1 Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey JF RMD Open JO RMD Open FD EULAR SP e001814 DO 10.1136/rmdopen-2021-001814 VO 7 IS 3 A1 Sattui, Sebastian Eduardo A1 Liew, Jean W A1 Kennedy, Kevin A1 Sirotich, Emily A1 Putman, Michael A1 Moni, Tarin T A1 Akpabio, Akpabio A1 Alpízar-Rodríguez, Deshiré A1 Berenbaum, Francis A1 Bulina, Inita A1 Conway, Richard A1 Singh, Aman Dev A1 Duff, Eimear A1 Durrant, Karen L A1 Gheita, Tamer A A1 Hill, Catherine L A1 Howard, Richard A A1 Hoyer, Bimba F A1 Hsieh, Evelyn A1 El Kibbi, Lina A1 Kilian, Adam A1 Kim, Alfred Hyoungju A1 Liew, David F L A1 Lo, Chieh A1 Miller, Bruce A1 Mingolla, Serena A1 Nudel, Michal A1 Palmerlee, Candace A A1 Singh, Jasvinder A A1 Singh, Namrata A1 Ugarte-Gil, Manuel Francisco A1 Wallace, John A1 Young, Kristen J A1 Bhana, Suleman A1 Costello, Wendy A1 Grainger, Rebecca A1 Machado, Pedro M A1 Robinson, Philip C A1 Sufka, Paul A1 Wallace, Zachary S A1 Yazdany, Jinoos A1 Harrison, Carly A1 Larché, Maggie A1 Levine, Mitchell A1 Foster, Gary A1 Thabane, Lehana A1 Rider, Lisa G A1 Hausmann, Jonathan S A1 Simard, Julia F A1 Sparks, Jeffrey A YR 2021 UL http://rmdopen.bmj.com/content/7/3/e001814.abstract AB Background We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.Methods From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.Results We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.Conclusion Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.Data are available on reasonable request. Researchers interested in performing additional analyses from survey data are invited to submit proposals through the COVID-19 Global Rheumatology Alliance at rheum-covid.org. For approved projects, we will be able to provide summary tables and data analyses as requested. We do not currently have IRB approval to make the raw data available to other researchers.